Instituting a New Central Line Policy to Decrease Central Line-associated Blood Stream Infection Rates During Induction Therapy in Pediatric Acute Lymphoblastic Leukemia Patients. Issue 7 (October 2020)

• Record Type: Journal Article
• Authors: Berger, Rebecca; Messina, Allison F.; Chandler, Nicole M.; Amankwah, Ernest K.; Shaw, Peter H.
• Is Part Of: Journal of pediatric hematology/oncology. Volume 42:Issue 7(2020)
• Publication Date: 2020-10
• Subjects: acute lymphoblastic leukemia -- CLABSI -- quality improvement -- thrombosis -- central venous lines; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000001748
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Background: Children with acute lymphoblastic leukemia (ALL) require central lines to facilitate their care. Peripherally inserted central catheters (PICCs) may have lower rates of central line-associated bloodstream infections (CLABSIs) versus other central lines. Objectives: The objective of this study was to compare the CLABSI rate in the first month of therapy after initiating a policy to place PICCs in new patients with severe neutropenia (SN) and Mediports in those with moderate-to-no neutropenia. We also examined thrombosis rates. Design/Method: We prospectively gathered data on new patients for 2.5 years following the policy change and retrospectively for the 2 years prior and compared rates of CLABSIs and thrombosis. Results: CLABSIs decreased in SN patients from 7.52/1000 to 3.11/1000 line days ( P =0.33). The CLABSI rate for all patients with SN who had a Mediport was 13.39/1000 versus 4.08/1000 line days for those that received PICCs ( P =0.15). The thrombosis rate for Mediport patients was 3.13 clots/1000 versus 7.65/1000 line days for PICC patients, but the difference was not significant ( P = 0.11). Conclusion: The differences observed suggest that placing PICCs versus Mediports in new ALL patients with SN may result in a lower incidence of CLABSIs in the first month of therapy without a significant increase in thrombosis.